Selenium, Zinc, Iron and Vitamin D: the building blocks of the thyroid
The thyroid has a remarkably short ingredient list. That makes it sensitive to a genuine deficiency. And it makes it sensitive to too much.
All guides from the thyroid cluster
The thyroid needs very few building blocks. That is why a single missing one can matter more here than elsewhere. And from that, the wrong conclusion is drawn all the time. Topping up without a deficiency is not a smaller version of topping up with a deficiency. It is something else entirely.
You are standing in front of a shelf. Or in front of a search result, which today is roughly the same thing.
Selenium 200 micrograms. Zinc plus selenium. The Hashimoto complex. Somewhere you read that selenium can lower antibodies, and that is even accurate. So you take it. Six months later the antibodies really are lower. And you feel exactly the same as before.
Many people with Hashimoto know this moment. In my consultations I hear about it often, and it is not imagination. It has an explanation that is missing from most guides: the antibody value and how you feel are two different things.
This article walks through the building blocks. With each one I separate three questions that get mixed up constantly. What does the thyroid need it for. What happens when it is missing. And what happens when you top it up although it is not missing. The third one is the decisive question.
What awaits you here
- Why an organ of 20 grams depends on so few trace elements
- Where exactly in hormone production each nutrient sits
- Selenium: the double role as protection and as converter
- What selenium changed in trials, and what it did not
- The upper limit, selenosis and the diabetes signal
- Iron: thyroid peroxidase is a heme enzyme
- Zinc at the receptor and the question of copper balance
- Vitamin D: strong association, cautious causality
- When measuring makes sense and when skipping it becomes risky
Why the thyroid depends on so few building blocks
Your thyroid weighs about 20 grams and has a single assignment: to build one molecule out of two ingredients, a molecule that co-determines the pace of your metabolism.
The two ingredients are iodine and tyrosine. Tyrosine is an amino acid from the protein in your food and forms the backbone. Iodine is attached to it. Four iodine atoms make T4, three make T3. At its core, that is all.
The difficult part is the attaching. Iodide, as it circulates in the blood, cannot simply be glued onto a protein. It has to be oxidised first, and for that the thyroid produces its own oxidising agent: hydrogen peroxide.
An enzyme system called dual oxidase generates it at the outer membrane of the thyroid cell, right where the cell borders the storage space. This arrangement has even been given its own name, the thyroxisome. Thyroid peroxidase takes the hydrogen peroxide, activates the iodide with it and builds it into thyroglobulin.
That is elegant. It is also risky.
The thyroid works with fire. It produces an aggressive molecule because it needs it as a tool, and it stands right next to that tool the entire time. A craftsman with a welding torch needs safety goggles. The safety goggles of this organ are built from selenium.
Here the short ingredient list becomes the issue. The enzymes that defuse hydrogen peroxide are selenoproteins. And the enzyme that manages the iodine incorporation needs iron. Two trace elements, two halves of the same reaction.
Josef Köhrle from the Institute of Experimental Endocrinology at the Charité in Berlin assembled in 2023 how iodine, selenium and iron interlock within the thyroid hormone system.
His description is precise: thyroid peroxidase is explicitly listed as a hemoprotein that requires locally produced hydrogen peroxide as a cofactor. The selenocysteine-containing proteins do two things at once, namely protection against exactly this hydrogen peroxide and activation of the hormones through the deiodinases.
For you that means: anyone talking about micronutrients and the thyroid is not talking about wellness. They are talking about three places in an enzyme chain where an element may be missing.
Köhrle J. Int J Mol Sci. 2023;24(4):3393. PMID: 36834802 · DOI: 10.3390/ijms24043393 [Mechanism Review]Two boundaries. If your values sit inside the reference range and you still do not feel well, there is usually more behind it than a trace element. That is covered in Normal values, symptoms anyway and in Functional hypothyroidism.
And iodine is only the contrast foil here. It is the raw material, not the protection. Too little slows production down, too much may, in people with the corresponding predisposition, favour an autoimmune thyroiditis. The whole story is in Putting iodine in context.
Where exactly each building block sits
- IodineThe raw material arrives. The sodium iodide symporter pulls iodide out of the blood into the cell and concentrates it there. No raw material, no hormone.
- TyrosineThe backbone stands ready. Thyroglobulin is a large protein with many tyrosine residues. The iodine is attached to those residues.
- Hydrogen peroxideThe tool is ignited. The dual oxidase system generates it at the apical membrane, organised in the thyroxisome. Without an oxidising agent, iodide stays unreactive.
- IronThe enzyme gets to work. Thyroid peroxidase only becomes active once it has bound heme, and heme contains iron. If iron is missing, this step may slow down.
- Selenium · protectionThe extinguisher stands ready. Glutathione peroxidases and thioredoxin reductases catch surplus hydrogen peroxide. Both families are selenoproteins.
- Selenium · conversionStorage form becomes active form. The deiodinases DIO1, DIO2 and DIO3 turn T4 into the more active T3 or into inactive reverse T3. All three are selenoproteins.
- ZincThe message arrives. The thyroid hormone receptor binds to DNA through a zinc finger structure. Without zinc this domain loses its shape, as shown in the test tube.
Vitamin D, magnesium and the B vitamins do not appear directly in this chain. They sit beside it: at the immune system, at energy supply and at absorption in the stomach. That is why they get their own sections and no place at the workbench.
The question is not: which nutrients are good for the thyroid. Framed that way, the answer is always all of them, and then you buy a capsule with fourteen ingredients.
The useful question is: at which point in this chain might something be stuck in my case, and can that be measured. Seven stations, seven different answers.
And now you know why an organ of 20 grams has such a short and at the same time such a demanding ingredient list.
Selenium: the protection inside its own fire
There is one sentence about selenium that appears in almost every guide, and it is even accurate: the thyroid contains more selenium per gram of tissue than other organs. What never follows is the question why.
The human genome contains 25 genes for proteins with built-in selenocysteine. This amino acid sits in the active centre of enzymes that juggle electrons. Three families are central for the thyroid.
The glutathione peroxidases defuse hydrogen peroxide and other reactive oxygen species. They are the safety goggles from the image above. The thioredoxin reductases keep the redox system of the cell in balance. And the deiodinases take iodine atoms off the hormones: DIO1 and DIO2 turn the storage hormone T4 into active T3, DIO3 turns it into reverse T3, the brake.
That is the double role: selenium protects the tissue, and at the same time it steers how much active hormone emerges from the storage form.
Josef Köhrle and Roland Gärtner, two authors who have shaped this field over decades, summarised in 2009 what selenium accomplishes in the thyroid.
They describe the gland as one of the tissues with the highest selenium content per unit of mass, comparable to other endocrine organs and to the brain. More important is a rarely quoted distinction: for the deiodinases the usual intake is mostly sufficient, while for full protection through glutathione peroxidases and thioredoxin reductases it may become tight.
For you that means: a selenium deficiency may show up first at the protection side and not at the conversion. That explains why in many selenium trials the hormone values stayed unchanged while something moved at the tissue level.
Köhrle J, Gärtner R. Best Pract Res Clin Endocrinol Metab. 2009;23(6):815-27. PMID: 19942156 · DOI: 10.1016/j.beem.2009.08.002 [Mechanism Review]How the conversion from T4 to T3 runs in detail and what may slow it down is covered in From T4 to T3: the conversion. Here the selenium link is enough: without selenium, no functioning deiodinases.
The supply situation in Europe
Selenium enters food through the plant, and the plant takes it from the soil. Selenium intake is therefore a geographic question.
Rita Stoffaneller and Nancy Morse searched the literature on selenium intake and selenium status in Europe, the United Kingdom and the Middle East for a systematic review published in 2015.
They evaluated 19 European and 15 Middle Eastern papers on intake, plus 92 papers on blood status. The result was consistent: a suboptimal selenium status is widespread in these regions, and Eastern European countries came out lower than Western European ones.
For you that means: the probability of being marginally supplied in Central Europe is real. But it is a probability across populations. Part of the context is that both authors worked as consultants for a supplement manufacturer.
Stoffaneller R, Morse NL. Nutrients. 2015;7(3):1494-1537. PMID: 25734564 · DOI: 10.3390/nu7031494 [Systematic Review]A map is not a diagnosis. That the soils in your region are low in selenium says something about averages and nothing about your blood value.
The jump from the map to the capsule is exactly the jump I would like to avoid. A measurement belongs between the two.
On top of that there is a mechanistic reason for restraint. The thyroid keeps its selenium concentration remarkably stable, even when intake drops. A moderate deficiency hits other tissues first.
Public health research offers a warning that rarely appears in guides. In regions with severe iodine and selenium deficiency at the same time, the iodine supply has to be corrected first. The other way round, giving selenium may favour an underactive state, because the deiodinases start up again and consume the scarce hormone reserve faster.
In Central Europe severe iodine deficiency is rare. The point stays instructive: building blocks interlock in a sequence, and that sequence belongs in medical hands, not in self-medication.
And now you know why selenium carries two jobs at once in this organ, and why geography explains something without diagnosing anything.
What selenium changed in trials, and what it did not
I am telling this part chronologically, because then you can see how a research field readjusted itself over twenty years.
Roland Gärtner and colleagues randomised 70 women with autoimmune thyroiditis and high antibodies. 36 received 200 micrograms of sodium selenite daily over three months, 34 received placebo, all of them were on levothyroxine.
The mean TPO antibody concentration fell in the selenium group to 63.6 percent of baseline (p equals 0.013), under placebo to 88 percent without statistical significance. In 9 people of the selenium group the antibodies afterwards sat inside the reference range, against 2 under placebo.
For you that means: the effect on the antibodies was real. One sentence from the same paper is almost never quoted with it: TSH, free T4 and free T3 stayed unchanged in both groups.
Gärtner R, Gasnier BCH, Dietrich JW et al. J Clin Endocrinol Metab. 2002;87(4):1687-91. PMID: 11932302 · DOI: 10.1210/jcem.87.4.8421 [RCT, n=70]A year later came the Athens trial. Leonidas Duntas gave 34 people 200 micrograms of selenomethionine in addition to levothyroxine, 31 received placebo, over six months. TPO antibodies fell by 55.5 percent after six months. Two details are regularly missing from German guides: the placebo group fell markedly as well, by 27 percent. And the selenium level did not correlate with thyroid hormones at the end.
Then came the brake.
Esther van Zuuren and colleagues examined all randomised trials on selenium in Hashimoto for the Cochrane Collaboration. Four trials with 463 participants met the criteria, all of them with unclear to high risk of bias.
The decisive finding is not a number but a gap: the pre-specified primary endpoint, health related quality of life, was not recorded in any of the four trials. The authors concluded that the evidence is neither sufficient to support efficacy nor to refute it.
For you that means: for twenty years, what is easy to measure was measured. How people actually felt was not in the study plan.
van Zuuren EJ, Albusta AY, Fedorowicz Z et al. Cochrane Database Syst Rev. 2013;(6):CD010223. PMID: 23744563 · DOI: 10.1002/14651858.CD010223.pub2 [Systematic Review]In 2021 the sharpest critical evaluation followed. Yuan Qiu and colleagues analysed 23 trials. TPO antibodies fell measurably, TSH did not change, and participants in the selenium groups reported adverse effects significantly more often. The conclusion is unusually direct: the current evidence does not justify the increasing use of selenium, even though the autoantibodies decline.
An overview from 2023 placed six systematic reviews with a total of 75 randomised trials side by side. Only one of the six counted as methodologically high quality, and the certainty of evidence was consistently low to very low.
Camilla Larsen and a Danish consortium, with Lutz Schomburg from the Charité as co-author, randomised 412 people with TPO antibodies of 100 IU/ml and above to 200 micrograms of selenium or placebo, in addition to their existing levothyroxine therapy, over twelve months. The primary endpoint was quality of life measured with ThyPRO-39, pre-specified in the protocol.
Quality of life improved in both groups. Between selenium and placebo there was no difference in any single scale after twelve months, the composite score was 28.8 against 28.0 (p equals 0.602). Splitting participants by baseline selenium status changed nothing either. Antibodies were lower under selenium (1,995 against 2,344 kIU/l), without a change in the levothyroxine dose or in the fT3 to fT4 ratio.
For you that means: the antibody value is a stand-in for something you actually want to know. In the largest and methodologically best trial, the stand-in moved and the thing itself stayed where it was.
Larsen C, Winther KH, Cramon PK et al. Eur Thyroid J. 2024;13(1):e230175. PMID: 38215286 · DOI: 10.1530/ETJ-23-0175 [RCT, n=412]There is one exception, the only selenium indication with guideline backing in Europe. Claudio Marcocci and the European EUGOGO group randomised 159 people with mild Graves' orbitopathy, meaning the eye involvement in Graves' disease, to selenium, pentoxifylline or placebo. After six months selenium was associated with better quality of life (p less than 0.001) and less eye involvement (p equals 0.01). The trial ran in a region with low selenium status, and exactly this limitation was carried into the guideline.
Eye symptoms in Graves' disease do not belong in self-treatment. Pressure behind the eyes, double vision, protruding eyes or deteriorating sight are reasons for a prompt appointment, ideally at a specialised centre. The European guideline explicitly stresses early referral.
The same applies to a racing heart, rhythm disturbances, marked restlessness with weight loss, or a pronounced slowing down with clouded consciousness. Those are situations for medical assessment, not for a capsule.
How antibodies behave in Hashimoto and what they tell you is covered in Lowering Hashimoto antibodies. Here only the building block perspective is of interest.
If your antibodies have fallen and you do not feel better, that is not a failure on your part and not imagination. It is exactly what the largest trial on this topic found.
The value and how you feel are two separate quantities. They can move independently of each other. Knowing that takes pressure out of the whole thing.
And now you know why the selenium picture sounds so contradictory: it is not. It measures two different things.
The other side of selenium: upper limit, selenosis and a diabetes signal
This is the section I consider the most important, because almost nobody writes it.
Selenium has a narrow window. The distance between what you need and what is too much is among the smallest in the entire nutrient field.
The EFSA panel on nutrition, novel foods and food allergens revised the tolerable upper intake level for selenium and adopted the opinion in November 2022.
The new value for adults sits at 255 micrograms per day, including pregnant and breastfeeding women. The critical endpoint was alopecia, meaning hair loss as an early sign of selenium overload, derived from a LOAEL of 330 micrograms taken from the SELECT trial with an uncertainty factor of 1.3. The value valid until then was 300 micrograms.
For you that means: the limit was moved downwards, not upwards. The 200 micrograms customary in trials sit below it, but not far below. Anyone who also has a combination product and selenium rich food comes closer than they think.
EFSA Panel on Nutrition, Novel Foods and Food Allergens. EFSA Journal. 2023;21(1):e07704. DOI: 10.2903/j.efsa.2023.7704 [Guideline]Too much selenium can lead to selenosis, and that creeps up slowly. Typical signs are hair loss, brittle nails, gastrointestinal complaints, a garlic-like breath odour, irritability and, in pronounced cases, nerve irritation.
Saverio Stranges and colleagues re-analysed the Nutritional Prevention of Cancer trial. 1,202 people without type 2 diabetes at baseline took 200 micrograms of selenium or placebo daily over an average of 7.7 years, in regions of the eastern United States with low selenium intake.
Type 2 diabetes occurred in 58 people under selenium and 39 under placebo, meaning 12.6 against 8.4 cases per 1,000 person years, hazard ratio 1.55 (1.03 to 2.33). In the top tertile of baseline selenium level it was 2.70 (1.30 to 5.61).
For you that means: those who were already well supplied and supplemented anyway carried the highest risk in this analysis. Honesty requires the caveats: diabetes was a secondary endpoint, the diagnoses were largely self-reported, and the group was older and not very diverse.
Stranges S, Marshall JR, Natarajan R et al. Ann Intern Med. 2007;147(4):217-23. PMID: 17620655 · DOI: 10.7326/0003-4819-147-4-200708210-00175 [RCT, n=1,202]An observation this unexpected needs a counter-check. In the SELECT trial with 35,533 men the relative risk for type 2 diabetes was 1.07 (confidence interval 0.94 to 1.22). The same direction, without statistical significance. So the signal does not disappear, but it is not proven either.
Why more is not better in well supplied people
With most vitamins we think in a straight line. Little is bad, more is better, plenty is at least not harmful. With selenium that does not hold.
Margaret Rayman put it into shape in a Lancet seminar in 2012: between selenium status and health there is a U-shaped relationship. Deficiency on the left, excess on the right, and between them a window narrower than most products suggest.
People with an adequate to high selenium status should not take selenium supplements. Supplementation can only achieve something when intake is inadequate.
Paraphrased from Margaret Rayman, Lancet 2012Margaret Rayman and colleagues randomised 501 older people in the United Kingdom to 100, 200 or 300 micrograms of selenium daily as selenium enriched yeast, or to placebo yeast, over six months.
Plasma selenium rose markedly in all active groups. Thyroid function did not change, in none of the three dose steps. The mean baseline value was 91 micrograms per litre and thus higher than in earlier trials with favourable effects.
For you that means: this is the cleanest evidence that topping up without a deficiency stays without consequence. Even 300 micrograms daily moved nothing in well supplied people.
Rayman MP, Thompson AJ, Bekaert B et al. Am J Clin Nutr. 2008;87(2):370-8. PMID: 18258627 · DOI: 10.1093/ajcn/87.2.370 [RCT, n=501]A review in Nature Reviews Endocrinology sums it up soberly: adverse effects appear at both ends of the intake range, the optimal window is narrow. The same group notes that selenium is nonetheless used widely in other thyroid conditions, despite the narrow recommendation.
A nutrient is not a wellness product. It is a dose. And every dose has two ends.
The toxicological question is not whether selenium is good or bad. It is: where do you stand on this U-curve. Without a measurement that is guesswork, and in the NPC trial exactly that guesswork came with a risk.
And now you know why with selenium I ask about the value first and not about the brand.
Iron: thyroid peroxidase is a heme enzyme
Many people have experienced their exhaustion being explained by iron deficiency. And many have also been told that the blood count is fine, so it cannot be that. Both fall short, and the reason is an enzyme.
Thyroid peroxidase, the very enzyme the antibodies are directed against in Hashimoto, is a hemoprotein. It only becomes active at the cell surface once it has bound heme. No iron, no heme, no active enzyme.
Sonja Hess and Michael Zimmermann fed 84 rats diets with different degrees of iron restriction over four weeks. Because iron deficiency reduces appetite, control groups were pair fed so that the effect of eating less could be calculated out.
Haemoglobin, T3 and T4 were lower in the iron deficient groups. Thyroid peroxidase activity per thyroid was reduced by 56, 45 and 33 percent, graded by the severity of the deficiency. Iron deficiency anaemia lowered it further and independently of the reduced food intake.
For you that means: the mechanism is quantified in the animal model, and the magnitude is considerable. These are rat data. They show that the connection exists, and say nothing about the threshold in humans.
Hess SY, Zimmermann MB, Arnold M et al. J Nutr. 2002;132(7):1951-5. PMID: 12097675 · DOI: 10.1093/jn/132.7.1951 [In vivo, rat]In humans there is interventional evidence from an entirely different context. In Côte d'Ivoire, children with goiter and iron deficiency anaemia responded markedly worse to iodised oil. Iron treatment improved the response, and in a randomised arm also the efficacy of iodised salt. An extreme situation, but the mechanism is thereby shown in humans too.
For everyday circumstances there are cross-sectional data. A meta-analysis of ten studies found lower values for TSH, free T4 and free T3 in iron deficiency, with very high heterogeneity, and additionally more frequent positive thyroid autoantibodies. In women of childbearing age the odds ratio for positive TPO antibodies was 1.89.
And then there is a finding that contradicts a widespread assumption. I consider it important enough not to leave it out.
Mohammadamin Parsaei and an international team, including Tim Korevaar from Rotterdam, analysed 47 studies with 53,152 pregnant women. They defined iron deficiency once through serum ferritin and once through haemoglobin.
Stratified by serum ferritin, there was no significant difference in TSH, free T4 or total T4. Stratified by haemoglobin there was: TSH sat at 2.31 against 1.75 mIU/l, free T4 at 10.7 against 13.3 pmol/l. In the meta-regression too, haemoglobin was linked with the thyroid values, ferritin was not.
For you that means: storage and function are not the same thing. In this very large analysis, function said more than storage. That does not devalue ferritin as a storage marker. It shows that a storage value alone does not predict the thyroid situation.
Parsaei M, Dashtkoohi M, Amirkhalili E et al. Front Endocrinol. 2025;16:1533169. PMID: 39944206 · DOI: 10.3389/fendo.2025.1533169 [Meta-analysis, k=47]Why is this not a setback for a functional point of view? Because it steers towards a better question. Ferritin is a storage protein and an inflammation marker at once. In silent inflammation it rises, although the available iron pool shrinks. The regulator behind that is called hepcidin, described in Iron, inflammation and the hepcidin blockade.
What iron deficiency otherwise does to the thyroid picture, especially in interplay with sleep, is covered in Iron deficiency, thyroid and sleep. I deliberately do not expand on it here.
Why several deficiencies often come together in Hashimoto
Autoimmune conditions like company. In Hashimoto, chronic atrophic gastritis occurs more often than chance would predict. It destroys the parietal cells in the stomach, and those produce intrinsic factor for B12 uptake and gastric acid for iron uptake. If both fall away, two deficiencies may arise at the same time, and neither of them is down to your diet.
A deficiency is a question, not an answer. If iron is missing, the interesting follow-up question is not which product it should be. It is: why is it missing.
Ate too little, lost too much, or did not absorb it. In Hashimoto the third possibility is more common than it gets discussed. And bleeding that does not belong to the menstrual cycle belongs assessed, not covered up.
And now you know why iron in the thyroid context is not only a question of tiredness, but one of enzyme chemistry.
Zinc and the question of copper balance
On the nutrient shelf zinc is the friendly all-rounder. For the thyroid its role is more specific and sits further back in the chain. Not at production, but at the message.
T3 is only a hormone when it gets read. It docks onto a receptor in the cell nucleus, and that receptor binds to DNA through a zinc finger structure of the Cys2-Cys2 type. Two zinc atoms hold the domain together like two clips holding an open book.
Patricia Franco and colleagues examined the DNA binding domains of several nuclear receptors, among them members of the thyroid hormone receptor family, with molecular biology methods.
The domains are of the Cys2-Cys2 zinc finger type, and their three-dimensional structure was indispensable for the interaction with further regulatory proteins. When the zinc was removed with chelating agents, this interaction collapsed.
For you that means: the mechanism is cleanly demonstrated, and it is demonstrated in the test tube. It does not follow that giving zinc improves the T3 effect in humans. It is at exactly this distinction that many guide texts move too fast.
Franco PJ, Li G, Wei LN. Mol Cell Endocrinol. 2003;206(1-2):1-12. PMID: 12943985 · DOI: 10.1016/s0303-7207(03)00254-5 [In vitro]What does the human side look like? Honestly, thin. The most cited paper dates from 1994. Of 134 people with disabilities, 13 had a low free T3 with normal T4, and in 9 of them a zinc deficiency was found. Under twelve months of zinc, free T3 and T3 rose back into the reference range. A case series with 13 people, without a control group.
Two randomised trials have tested zinc in hypothyroidism. In one with 68 women, free T3 rose in the zinc groups, yet in the direct group comparison no significant treatment effects were found. In the other with 86 people, free T4 rose under zinc, magnesium and vitamin A, and the inflammation marker hs-CRP fell.
The hs-CRP finding fits the lens of clinical psychoneuroimmunology: trace elements and inflammation are connected, and the thyroid sits at this interface between immune system and hormonal axis. The limitation is hard, it was a combination product.
A systematic review from 2023 covering thirteen randomised trials puts it without varnish: the efficacy of zinc, selenium and their combination on thyroid function cannot currently be determined with confidence. The observation regarding free T3 in hypothyroidism rests on a single trial.
What a genuine, pronounced deficiency looks like is shown by a case report from Kobe. A man with a severely shortened small intestine received artificial nutrition without trace elements and showed an unusual pattern: high TSH and high free T4 with low free T3. Only under selenium, and then additionally under zinc, did the values improve again. A single case under conditions that have nothing to do with everyday life.
The flip side: zinc displaces copper
Zinc and copper share absorption routes in the intestinal lining. Zinc stimulates the formation of metallothionein there, which binds copper and is excreted with the shed cell. A lot of zinc over a long time may therefore lead to a copper deficiency.
Monte Willis and colleagues described three men in whom the diagnosis of a copper deficiency was first suspected through a bone marrow examination.
Two of the three had a progressive, disabling peripheral neuropathy over months with anaemia and severe neutropenia, the third took zinc because of a zinc deficiency disorder and developed anaemia and neutropenia under it. In all cases the copper deficiency was confirmed in the laboratory and attributed to zinc excess.
For you that means: this concerns clearly elevated amounts over long periods, not every supplement. But the consequences are serious enough not to dismiss zinc as harmless.
Willis MS, Monaghan SA, Miller ML et al. Am J Clin Pathol. 2005;123(1):125-31. PMID: 15762288 · DOI: 10.1309/v6gvyw2qtyd5c5pj [Case Series, n=3]With zinc the amount is not the only quantity. The ratio to copper has a say as well.
That is why taking it continuously over months is something different from a short phase with a documented deficiency. Both belong in medical supervision, and with an eye on both elements.
And now you know why zinc gets a place at the workbench in this article, but not the leading role.
Vitamin D: strong association, cautious causality
With vitamin D and Hashimoto the data are more extensive than with zinc, in places even of high quality, and yet the conclusion is harder. That is down to a question almost no guide asks: is the low level the cause of the autoimmune condition, or its consequence?
Undisputed is this: people with Hashimoto have on average lower 25-hydroxy vitamin D levels, and between that level and the height of TPO antibodies there is an inverse relationship in many investigations.
Three meta-analyses have examined what giving vitamin D changes. The largest, with twelve randomised trials and 862 people, found markedly falling TPO and thyroglobulin antibodies. One side finding is revealing: active vitamin D lowered the antibodies more strongly than native D2 or D3, which speaks more for an immunomodulating role than for correcting a deficiency.
An older analysis of six trials with 344 people found the same pattern with a timeline: after six months the TPO antibodies fell markedly, after three months or less they did not. Immune processes take time.
Hui Jiang and colleagues analysed seven cohorts from six clinical trials with 258 people with Hashimoto.
The 25-hydroxy vitamin D level rose markedly under supplementation, as expected, and the TPO antibodies fell significantly. For TSH, free T3 and free T4 no difference was found, and none for thyroglobulin antibodies either. The authors themselves put it very directly: this suggests that vitamin D is not connected with thyroid function in Hashimoto.
For you that means: it is the same separation as with selenium. The immune marker moves, the hormone axis does not. Whoever knows that calibrates their expectations differently.
Jiang H, Chen X, Qian X, Shao S. J Clin Pharm Ther. 2022;47(6):767-775. PMID: 34981556 · DOI: 10.1111/jcpt.13605 [Meta-analysis, k=6]Jill Hahn and Karen Costenbader randomised 25,871 people in a two by two design to vitamin D 2,000 IU daily, omega-3 fatty acids, both or placebo. Median follow-up 5.3 years. The primary endpoint was any newly occurring autoimmune disease, self-reported and subsequently confirmed by record review, explicitly including autoimmune thyroid disease.
In the vitamin D arm 123 confirmed autoimmune diseases occurred against 155 under placebo. Hazard ratio 0.78 (confidence interval 0.61 to 0.99, p equals 0.05). The omega-3 arm alone did not reach significance.
For you that means: this is a genuine interventional finding. Honesty requires three limitations. The p value sits exactly at the boundary, the endpoint was the sum of all autoimmune diseases and not Hashimoto alone, and the participants were older.
Hahn J, Cook NR, Alexander EK et al. BMJ. 2022;376:e066452. PMID: 35082139 · DOI: 10.1136/bmj-2021-066452 [RCT, n=25,871]That leaves the causality question. For that there is Mendelian randomisation. It uses genetic variants that influence the vitamin D level as a kind of natural randomised experiment, and confounders drop away.
Two independent papers did this in 2024. One found, per standard deviation of higher 25-hydroxy vitamin D, a 12 percent lower risk for a high TSH, but called the effect suggestive itself. The second found higher levels associated with a lower risk for autoimmune thyroiditis, odds ratio 0.499, while for Graves' disease it found nothing.
Other data and the lack of sufficient interventional evidence suggest that a low vitamin D status is more the result of the autoimmune disease process than its cause.
Paraphrased from Hu and Rayman, Thyroid 2017That sentence comes from the journal of the American Thyroid Association, not from the supplement scene. A documented vitamin D deficiency nevertheless stays a documented deficiency, regardless of the direction. Fitting alongside this are Vitamin D deficiency, sun and winter and Taking vitamin D correctly.
The question is not whether vitamin D is good. It is what you expect from it.
Whoever expects the antibodies to fall has, according to the evidence so far, good chances. Whoever expects TSH, fT3 and fT4 to change will be disappointed after three meta-analyses. Knowing both at the same time is the whole difference.
And now you know why, of all things, the vitamin with the best data gets the most cautious section here.
Tyrosine, magnesium and the B vitamins: the supporting roles
Three substances appear regularly in thyroid products, and all three deserve an honest classification.
Tyrosine is the case that surprised me most. That it forms the backbone of every thyroid hormone is undisputed and stands in every textbook. The step from there to a capsule is nevertheless not covered.
I searched specifically for human studies showing a benefit of tyrosine intake beyond normal nutrition. I found none that holds up. The reason is plausible: with normal protein intake, tyrosine is not the limiting factor, and the body additionally makes it from phenylalanine. A building block is only a lever when it is scarce.
Magnesium has exactly one larger paper, and that one is cross-sectional. In a Chinese investigation of 1,257 people, values below 0.55 mmol/l, which affected 5.9 percent, came with a raised risk for positive thyroglobulin antibodies and for Hashimoto thyroiditis, with odds ratios between 2.7 and 3.2.
A cross-section cannot show direction. Mechanistically plausible, human studies still thin, that is how I would classify it. The cofactors of energy metabolism are covered in From calorie to energy.
Vitamin B12 is the most interesting of the three, because here it is not about the thyroid itself but about the stomach.
Rosane Ness-Abramof and colleagues measured serum B12 in 115 people with autoimmune thyroid disease and went further where values were low.
32 people, meaning 28 percent, had low B12 values. Five of those with high gastrin underwent gastroscopy with biopsy, and in all five an atrophic gastritis was found. Among those with low B12 the frequency of pernicious anaemia was 31 percent.
For you that means: the same autoimmune gastritis that blocks B12 also blocks iron absorption. That explains why in Hashimoto several deficiencies occur simultaneously more often than chance would predict, and why the cause may lie in the stomach and not on the plate.
Ness-Abramof R, Nabriski DA, Braverman LE et al. Am J Med Sci. 2006;332(3):119-22. PMID: 16969140 · DOI: 10.1097/00000441-200609000-00004 [Cohort, n=115]If several values are low in you at the same time, that is rarely coincidence and almost never a dietary mistake. It is a hint towards a shared cause further up the chain.
Three separate products then fill three gaps. The question about the stomach may lead to the cause behind them.
And now you know why I am sceptical about combination products with many ingredients: they answer all questions at once and none of them properly.
Measuring or supplementing: the honest decision path
Now it gets practical, though without a copyable recipe. What makes sense in your situation is decided in a medical conversation with your values on the table.
A measurement makes sense when you have an assumption beforehand that it can confirm or refute. A product without a value in front of it is a shot in the dark, and with selenium it is a shot at a U-curve.
What can be measured, and where the limits are
With selenium the usual route is the serum value, sometimes whole blood. The functionally more interesting marker is selenoprotein P. It is produced in the liver, preferentially supplies endocrine glands and the brain, and has a notable property: it rises with supply until a saturated status is reached, and then forms a plateau. Above that, the marker says nothing more about any gain.
Qian Sun and the group around Lutz Schomburg at the Charité developed an assay for autoantibodies against selenoprotein P and applied it to sera from thyroid patients and healthy controls.
Such autoantibodies were found in 6.6 percent of people with Hashimoto compared with 0.3 percent of controls. The affected sera showed higher total selenium values (85.3 against 77.1 µg/l) alongside lower glutathione peroxidase 3 activity. In cell culture the antibodies inhibited selenium uptake.
For you that means: a normal or even high selenium value in blood may mask a functional undersupply, because the transport is stuck. This concerns a minority, and it rests on a single paper so far. As a hypothesis it is elegant, as a clinical standard it is not yet established.
Sun Q, Mehl S, Renko K et al. Int J Mol Sci. 2021;22(23):13088. PMID: 34884891 · DOI: 10.3390/ijms222313088 [In vitro]With iron the rule is: ferritin is the storage, the blood count shows the function, the two may drift apart, and ferritin additionally rises with inflammation. With zinc the serum value is unreliable, and anyone taking it for longer should keep copper in mind. Agreed target ranges for selenium and zinc in thyroid conditions do not exist to this day.
Why guideline and functional view sound different here
The German primary care S2k guideline of the DEGAM on the elevated TSH value states clearly that there is no evidence that additional trace elements, herbal products or food supplements bring a patient relevant benefit in hypothyroidism and Hashimoto thyroiditis.
It names its own reasoning: the trials that tend to recommend selenium used no validated measurement instruments for relevant endpoints such as quality of life. That matches the Cochrane finding. A primary care guideline has the task of avoiding overtreatment across the general population.
The statement no patient relevant benefit is a statement about unselected populations. It is not a statement about the individual person with a laboratory documented deficiency.
Exactly that trial is still missing: selenium exclusively in documented deficiency, with quality of life as a pre-specified endpoint. Until it exists, the honest answer is neither yes nor no, but untested. The European EUGOGO guideline shows how narrowly a justified exception can be framed.
The American ATA guideline establishes levothyroxine as the standard. Micronutrients were not among the therapy alternatives examined there at all, so it is not a rejection but a blank space.
Levothyroxine, antithyroid drugs and every other long-term medication are never stopped, reduced or switched on your own initiative. Micronutrients do not replace hormone substitution, and nothing in this article is an argument for questioning an existing therapy. Changes belong exclusively in medical supervision, with monitoring of the values.
One practical point the guideline names as well: levothyroxine is taken with a time gap to food supplements. Iron, calcium and antacids impede its absorption. Customary is taking it on an empty stomach at least 30 minutes before the meal, or alternatively in the evening with a clear gap.
In pregnancy different target ranges apply for the thyroid values, and the iron requirement rises markedly. That belongs in close medical care. For selenium in pregnancy the DEGAM explicitly derives no recommendation, because the evidence is too weak.
What belongs in medical assessment and not in supplementation
- A newly palpable nodule at the neck or a rapidly growing goiter. Both belong examined, more on that in Assessing nodules and goiter.
- A racing heart or rhythm disturbances, especially together with inner restlessness, tremor and weight loss.
- Eye symptoms in Graves' disease, meaning pressure behind the eyes, double vision, protruding eyes or deteriorating sight.
- A pronounced slowing down with confusion, strong cold sensitivity or clouded consciousness. That is an emergency.
- Bleeding outside the menstrual cycle or very heavy periods with iron deficiency. The cause belongs found, not covered up.
Which values carry information and in what order to look at them is covered in Thyroid blood values: which ones really count.
Measuring first and deciding afterwards is not a brake. It is the difference between an answer and an attempt.
In my clinical experience people become calmer as soon as they have a value, even when it is unremarkable. Not because the value changes anything, but because it closes an open question. That is not a study statement, that is my observation from the consultation room.
And now you know why the most interesting question with micronutrients is not what you should take, but what is actually missing in you.
Frequently asked questions about micronutrients and the thyroid
Which micronutrients does the thyroid actually need?
The ingredient list is short. Iodine is the raw material, tyrosine the backbone, iron sits in the heme of thyroid peroxidase, selenium protects against the hydrogen peroxide and supplies all three deiodinases. Zinc sits at the receptor. A building block only counts when it is genuinely missing.
Why is the thyroid so dependent on selenium?
Because it works with fire. To bind iodine it produces hydrogen peroxide as a tool. The glutathione peroxidases and thioredoxin reductases that catch it are selenoproteins. That is why the gland is among the tissues with the highest selenium content per unit of mass. 25 human genes encode selenoproteins, among them DIO1, DIO2 and DIO3.
How much selenium was used in the Hashimoto trials?
Almost all intervention trials worked with 200 micrograms per day: Gärtner 2002 over three months, Duntas 2003 over six, CATALYST over twelve. Rayman 2008 tested 100, 200 and 300 micrograms. Those are study doses from the literature and not a recommendation for you. Your situation belongs in a medical conversation with a laboratory value in front of it.
Does selenium lower thyroid antibodies?
In many trials yes, and fairly reproducibly. With Gärtner the mean TPO antibody concentration fell to 63.6 percent of baseline, with Duntas by 55.5 percent after six months. Two limitations belong with that: the placebo groups partly fell as well, and an overview of 75 randomised trials rated the certainty of evidence as low to very low.
If my antibodies drop, will I feel better too?
That is exactly what CATALYST examined, the largest trial on this so far. 412 people, twelve months, 200 micrograms of selenium against placebo, quality of life as the pre-specified primary endpoint. There was no difference in any scale of the ThyPRO-39. Antibodies were lower under selenium, without the levothyroxine dose changing. An existing levothyroxine therapy is therefore never altered on your own, that belongs in medical supervision.
At what amount does selenium become dangerous?
The European Food Safety Authority set the tolerable upper intake level for adults at 255 micrograms per day in 2023, pregnant women included. The critical endpoint was hair loss, derived from a LOAEL of 330 micrograms with an uncertainty factor of 1.3. The previous value was 300 micrograms, so the limit was lowered.
Is it true that selenium may raise the risk of diabetes?
There is a signal worth taking seriously, but no proof. In the NPC trial 1,202 people took 200 micrograms of selenium or placebo over 7.7 years. Type 2 diabetes occurred at 12.6 against 8.4 cases per 1,000 person years, hazard ratio 1.55, in the top selenium tertile 2.70. SELECT showed the same direction without significance.
Are Brazil nuts enough as a selenium source?
Brazil nuts are the richest food source of selenium there is, and that is precisely their problem: the content varies enormously with the growing region. A handful can be harmless or clearly above the upper intake level, and you cannot tell by looking at the nut. As a controllable source they work poorly.
What does iron have to do with the thyroid?
Thyroid peroxidase is a heme enzyme. It only becomes active once it has bound heme, and heme needs iron. In the rat model enzyme activity fell by 33 to 56 percent depending on the severity of the iron deficiency. In humans, a meta-analysis of ten cross-sectional studies shows lower fT4 and fT3 values.
Which ferritin value is relevant for the thyroid?
Honesty pays here. In a meta-analysis of 53,152 pregnant women, haemoglobin predicted the thyroid values, serum ferritin did not. That does not devalue ferritin as a storage marker, it only shows that storage and function are two different things. The target value debate belongs in a medical conversation.
Can a zinc deficiency mimic hypothyroidism?
A genuine, pronounced zinc deficiency can shift the picture, there are case reports for that. Among 13 people with low free T3, 9 had a zinc deficiency, and under twelve months of zinc, fT3 and T3 rose back into the reference range. A very small group without a control group. Without a documented deficiency nothing can be derived from it.
How much zinc is too much, and what happens to copper then?
Zinc and copper share absorption routes in the gut, which is why high amounts of zinc over long periods can trigger a copper deficiency. A case series describes three men with anaemia, severe neutropenia and progressive neuropathy. This is about clearly elevated amounts, not about every supplement. With zinc the ratio counts, not only the amount.
What can be expected from vitamin D in Hashimoto?
Three meta-analyses consistently show falling TPO antibodies, with standardised mean differences between minus 0.55 and minus 1.11. None shows a consistent effect on TSH, fT3 or fT4. In VITAL, 22 percent fewer autoimmune diseases occurred under 2,000 IU daily over 5.3 years, hazard ratio 0.78 at p equals 0.05. A low level is, according to Hu and Rayman, more likely a consequence than a cause.
Should I simply take selenium, zinc or vitamin D as a precaution?
With selenium the data argue against it. There is a U-shaped relationship between selenium status and health, and in well supplied people nothing moved with up to 300 micrograms daily. The Lancet seminar states explicitly that people with an adequate status should not take selenium supplements. The sensible order is: first an assumption, then measuring, then a medical conversation.
Where the topic continues
Building blocks of the thyroid
Selenium, iron, zinc, vitamin D
this articleVitamin D in winter
Sun, latitude and why the level swings with the season
Taking vitamin D
What to keep in mind with magnesium and K2
Gut barrier and zonulin
Why absorption and autoimmunity converge at the gut
Scientific sources
- Köhrle J. Selenium, Iodine and Iron: Essential Trace Elements for Thyroid Hormone Synthesis and Metabolism. Int J Mol Sci. 2023;24(4):3393. PMID: 36834802 · DOI: 10.3390/ijms24043393 [Mechanism Review]
- Köhrle J, Gärtner R. Selenium and thyroid. Best Pract Res Clin Endocrinol Metab. 2009;23(6):815-27. PMID: 19942156 · DOI: 10.1016/j.beem.2009.08.002 [Mechanism Review]
- Silvestrini A, Mordente A, Martino G et al. The Role of Selenium in Oxidative Stress and in Nonthyroidal Illness Syndrome. Curr Med Chem. 2020;27(3):423-449. PMID: 29421998 · DOI: 10.2174/0929867325666180201111159 [Mechanism Review]
- Souza LSL de, Campos RO, Braga JS et al. Selenium nutritional status and thyroid dysfunction. Arch Endocrinol Metab. 2025;69(1):e230348. PMID: 39992731 · DOI: 10.20945/2359-4292-2023-0348 [Review]
- Schomburg L. Selenoprotein P: Selenium transport protein, enzyme and biomarker of selenium status. Free Radic Biol Med. 2022;191:150-163. PMID: 36067902 · DOI: 10.1016/j.freeradbiomed.2022.08.022 [Mechanism Review]
- Sun Q, Mehl S, Renko K et al. Natural Autoimmunity to Selenoprotein P Impairs Selenium Transport in Hashimoto's Thyroiditis. Int J Mol Sci. 2021;22(23):13088. PMID: 34884891 · DOI: 10.3390/ijms222313088 [In vitro]
- Stoffaneller R, Morse NL. A review of dietary selenium intake and selenium status in Europe and the Middle East. Nutrients. 2015;7(3):1494-1537. PMID: 25734564 · DOI: 10.3390/nu7031494 [Systematic Review] · conflict of interest declared by the authors in the original
- Rayman MP. Selenium and human health. Lancet. 2012;379(9822):1256-68. PMID: 22381456 · DOI: 10.1016/S0140-6736(11)61452-9 [Review]
- Gärtner R, Gasnier BCH, Dietrich JW et al. Selenium supplementation in patients with autoimmune thyroiditis decreases thyroid peroxidase antibodies concentrations. J Clin Endocrinol Metab. 2002;87(4):1687-91. PMID: 11932302 · DOI: 10.1210/jcem.87.4.8421 [RCT, n=70]
- Duntas LH, Mantzou E, Koutras DA. Effects of a six month treatment with selenomethionine in patients with autoimmune thyroiditis. Eur J Endocrinol. 2003;148(4):389-93. PMID: 12656658 · DOI: 10.1530/eje.0.1480389 [RCT, n=65]
- van Zuuren EJ, Albusta AY, Fedorowicz Z et al. Selenium supplementation for Hashimoto's thyroiditis. Cochrane Database Syst Rev. 2013;(6):CD010223. PMID: 23744563 · DOI: 10.1002/14651858.CD010223.pub2 [Systematic Review]
- Wang YS, Liang SS, Ren JJ et al. The Effects of Selenium Supplementation in the Treatment of Autoimmune Thyroiditis: An Overview of Systematic Reviews. Nutrients. 2023;15(14):3194. PMID: 37513612 · DOI: 10.3390/nu15143194 [Systematic Review]
- Qiu Y, Xing Z, Xiang Q et al. Insufficient evidence to support the clinical efficacy of selenium supplementation for patients with chronic autoimmune thyroiditis. Endocrine. 2021;73(2):384-397. PMID: 33774780 · DOI: 10.1007/s12020-021-02642-z [Meta-analysis, k=23]
- Larsen C, Winther KH, Cramon PK et al. Selenium supplementation and placebo are equally effective in improving quality of life in patients with hypothyroidism (CATALYST). Eur Thyroid J. 2024;13(1):e230175. PMID: 38215286 · DOI: 10.1530/ETJ-23-0175 [RCT, n=412]
- Winther KH, Watt T, Bjørner JB et al. The chronic autoimmune thyroiditis quality of life selenium trial (CATALYST): study protocol. Trials. 2014;15:115. PMID: 24716668 · DOI: 10.1186/1745-6215-15-115 [Review, study protocol]
- Marcocci C, Kahaly GJ, Krassas GE et al. Selenium and the course of mild Graves' orbitopathy. N Engl J Med. 2011;364(20):1920-31. PMID: 21591944 · DOI: 10.1056/NEJMoa1012985 [RCT, n=159]
- Winther KH, Rayman MP, Bonnema SJ, Hegedüs L. Selenium in thyroid disorders: essential knowledge for clinicians. Nat Rev Endocrinol. 2020;16(3):165-176. PMID: 32001830 · DOI: 10.1038/s41574-019-0311-6 [Review]
- Rayman MP, Thompson AJ, Bekaert B et al. Randomized controlled trial of the effect of selenium supplementation on thyroid function in the elderly in the United Kingdom. Am J Clin Nutr. 2008;87(2):370-8. PMID: 18258627 · DOI: 10.1093/ajcn/87.2.370 [RCT, n=501]
- Stranges S, Marshall JR, Natarajan R et al. Effects of long-term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Ann Intern Med. 2007;147(4):217-23. PMID: 17620655 · DOI: 10.7326/0003-4819-147-4-200708210-00175 [RCT, n=1,202]
- Lippman SM, Klein EA, Goodman PJ et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers (SELECT). JAMA. 2009;301(1):39-51. PMID: 19066370 · DOI: 10.1001/jama.2008.864 [RCT, n=35,533]
- EFSA Panel on Nutrition, Novel Foods and Food Allergens. Scientific opinion on the tolerable upper intake level for selenium. EFSA Journal. 2023;21(1):e07704. DOI: 10.2903/j.efsa.2023.7704 [Guideline]
- Hess SY, Zimmermann MB, Arnold M et al. Iron deficiency anemia reduces thyroid peroxidase activity in rats. J Nutr. 2002;132(7):1951-5. PMID: 12097675 · DOI: 10.1093/jn/132.7.1951 [In vivo, rat]
- Zimmermann MB, Köhrle J. The impact of iron and selenium deficiencies on iodine and thyroid metabolism. Thyroid. 2002;12(10):867-78. PMID: 12487769 · DOI: 10.1089/105072502761016494 [Mechanism Review]
- Zimmermann MB. Iron status influences the efficacy of iodine prophylaxis in goitrous children in Côte d'Ivoire. Int J Vitam Nutr Res. 2002;72(1):19-25. PMID: 11887748 · DOI: 10.1024/0300-9831.72.1.19 [Review, intervention series with randomised arm]
- Garofalo V, Condorelli RA, Cannarella R et al. Relationship between Iron Deficiency and Thyroid Function: A Systematic Review and Meta-Analysis. Nutrients. 2023;15(22):4790. PMID: 38004184 · DOI: 10.3390/nu15224790 [Meta-analysis, k=10]
- Luo J, Wang X, Yuan L, Guo L. Iron Deficiency, a Risk Factor of Thyroid Disorders in Reproductive-Age and Pregnant Women. Front Endocrinol. 2021;12:629831. PMID: 33716980 · DOI: 10.3389/fendo.2021.629831 [Meta-analysis]
- Parsaei M, Dashtkoohi M, Amirkhalili E et al. Association of iron status indicators with thyroid hormone concentrations during pregnancy. Front Endocrinol. 2025;16:1533169. PMID: 39944206 · DOI: 10.3389/fendo.2025.1533169 [Meta-analysis, k=47, n=53,152]
- Franco PJ, Li G, Wei LN. Interaction of nuclear receptor zinc finger DNA binding domains with histone deacetylase. Mol Cell Endocrinol. 2003;206(1-2):1-12. PMID: 12943985 · DOI: 10.1016/s0303-7207(03)00254-5 [In vitro]
- Nishiyama S, Futagoishi-Suginohara Y, Matsukura M et al. Zinc supplementation alters thyroid hormone metabolism in disabled patients with zinc deficiency. J Am Coll Nutr. 1994;13(1):62-7. PMID: 8157857 · DOI: 10.1080/07315724.1994.10718373 [Case Series, n=13]
- Mahmoodianfard S, Vafa M, Golgiri F et al. Effects of Zinc and Selenium Supplementation on Thyroid Function in Overweight and Obese Hypothyroid Female Patients. J Am Coll Nutr. 2015;34(5):391-9. PMID: 25758370 · DOI: 10.1080/07315724.2014.926161 [RCT, n=68]
- Rabbani E, Golgiri F, Janani L et al. Randomized Study of the Effects of Zinc, Vitamin A, and Magnesium Co-supplementation on Thyroid Function, Oxidative Stress, and hs-CRP. Biol Trace Elem Res. 2021;199(11):4074-4083. PMID: 33409923 · DOI: 10.1007/s12011-020-02548-3 [RCT, n=86]
- Zavros A, Giannaki CD, Aphamis G et al. The Effects of Zinc and Selenium Supplementation on Body Composition and Thyroid Function in Individuals with Overweight or Obesity. J Diet Suppl. 2023;20(4):643-671. PMID: 35532055 · DOI: 10.1080/19390211.2022.2072044 [Systematic Review]
- Nagano K, Motomura Y, Bando H et al. Thyroid dysfunction due to trace element deficiency: not only selenium but also zinc. Hormones (Athens). 2024;23(4):675-681. PMID: 38625626 · DOI: 10.1007/s42000-024-00550-1 [Case Report, n=1]
- Willis MS, Monaghan SA, Miller ML et al. Zinc-induced copper deficiency: a report of three cases initially recognized on bone marrow examination. Am J Clin Pathol. 2005;123(1):125-31. PMID: 15762288 · DOI: 10.1309/v6gvyw2qtyd5c5pj [Case Series, n=3]
- Hahn J, Cook NR, Alexander EK et al. Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial. BMJ. 2022;376:e066452. PMID: 35082139 · DOI: 10.1136/bmj-2021-066452 [RCT, n=25,871]
- Tang J, Shan S, Li F, Yun P. Effects of vitamin D supplementation on autoantibodies and thyroid function in patients with Hashimoto's thyroiditis. Medicine (Baltimore). 2023;102(52):e36759. PMID: 38206745 · DOI: 10.1097/MD.0000000000036759 [Meta-analysis, k=12, n=862]
- Wang S, Wu Y, Zuo Z et al. The effect of vitamin D supplementation on thyroid autoantibody levels in the treatment of autoimmune thyroiditis. Endocrine. 2018;59(3):499-505. PMID: 29388046 · DOI: 10.1007/s12020-018-1532-5 [Meta-analysis, k=6, n=344]
- Jiang H, Chen X, Qian X, Shao S. Effects of vitamin D treatment on thyroid function and autoimmunity markers in patients with Hashimoto's thyroiditis. J Clin Pharm Ther. 2022;47(6):767-775. PMID: 34981556 · DOI: 10.1111/jcpt.13605 [Meta-analysis, k=6, n=258]
- Pleić N, Babić Leko M, Gunjača I, Zemunik T. Vitamin D and thyroid function: A Mendelian randomization study. PLoS One. 2024;19(6):e0304253. PMID: 38900813 · DOI: 10.1371/journal.pone.0304253 [Cohort, Mendelian randomisation]
- Yu Y, Yang X, Wu J et al. A Mendelian randomization study of the effect of serum 25-hydroxyvitamin D levels on autoimmune thyroid disease. Front Immunol. 2024;14:1298708. PMID: 38259461 · DOI: 10.3389/fimmu.2023.1298708 [Cohort, Mendelian randomisation]
- Wang K, Wei H, Zhang W et al. Severely low serum magnesium is associated with increased risks of positive anti-thyroglobulin antibody and hypothyroidism. Sci Rep. 2018;8(1):9904. PMID: 29967483 · DOI: 10.1038/s41598-018-28362-5 [Cohort, cross-sectional, n=1,257]
- Ness-Abramof R, Nabriski DA, Braverman LE et al. Prevalence and evaluation of B12 deficiency in patients with autoimmune thyroid disease. Am J Med Sci. 2006;332(3):119-22. PMID: 16969140 · DOI: 10.1097/00000441-200609000-00004 [Cohort, cross-sectional, n=115]
- Hu S, Rayman MP. Multiple Nutritional Factors and the Risk of Hashimoto's Thyroiditis. Thyroid. 2017;27(5):597-610. PMID: 28290237 · DOI: 10.1089/thy.2016.0635 [Review]
- DEGAM. Erhöhter TSH-Wert in der Hausarztpraxis. S2k guideline, AWMF register no. 053-046, version 2.4, status 04/2023. AWMF register [Guideline] · no DOI, the reference is the AWMF register number
- Bartalena L, Kahaly GJ, Baldeschi L et al. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy. Eur J Endocrinol. 2021;185(4):G43-G67. PMID: 34297684 · DOI: 10.1530/EJE-21-0479 [Guideline]
- Jonklaas J, Bianco AC, Bauer AJ et al. Guidelines for the Treatment of Hypothyroidism: American Thyroid Association Task Force on Thyroid Hormone Replacement. Thyroid. 2014;24(12):1670-1751. PMID: 25266247 · DOI: 10.1089/thy.2014.0028 [Guideline]